How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
From the HRB Clinical Research Facility, National University of Ireland Galway, Galway, Ireland. d.sexton1@nuigalway.ie.
Donal J
DJ
Sexton
D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D059347:Cardio-Renal Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D015897:Comorbidity; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000503:physiopathology*; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists
cardio-renal syndrome; heart failure